Article

Alcon withdraws anecortave application

Fort Worth, TX?Alcon Inc. has withdrawn its application for European marketing authorization for anecortave acetate suspension for depot injection (Retaane) 30 mg/ml after being told that more clinical data would be necessary for approval.

Fort Worth, TX-Alcon Inc. has withdrawn its application for European marketing authorization for anecortave acetate suspension for depot injection (Retaane) 30 mg/ml after being told that more clinical data would be necessary for approval.

The company said in a prepared statement that the European Medicines Agency and the FDA had informed Alcon that it would need additional clinical data from existing and/or new clinical trials to support approval.

Alcon said it is revising its clinical strategy and plans to continue developing the drug for wet age-related macular degeneration in the United States, Europe, and key markets around the world. No timeframe was announced.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.